Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 04, 2026, titled "OneSource Supports Second Generic Semaglutide Approval in Canada-Enables commercialisation for the first two entrants in the world s second-largest semaglutide market".
Press Release May 04 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
OneSource Specialty Pharma Limited has issued a press release regarding the approval of a second generic semaglutide in Canada, enabling commercialization for its partners in this significant market. The approval reflects a successful collaboration between OneSource and its partner Orbicular, showcasing OneSource's capabilities in manufacturing and supporting complex pharmaceutical products. CEO Neeraj Sharma emphasized the importance of these approvals for their global customers and the strength of their CDMO platform.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
OneSource Specialty Pharma Limited on 6ix
Earlier from OneSource Specialty Pharma
- Press Release Apr 29 2026
- Press Release Apr 21 2026
- Press Release Feb 11 2026
- Press Release Nov 11 2025
- Press Release Aug 04 2025
Later from OneSource Specialty Pharma
- Press Release May 13 2026
- Onesource Specialty Pharma Limited Press Release Jul 24 2026
- Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
- Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru".
Follow OneSource Specialty Pharma into a list and get an email when it puts out news.
Follow OneSource Specialty Pharma